Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LNTH Lantheus	$59.16 +5.4%	$71.87	$47.25 ▼ $118.21	$3.82B	0.14	2.33 million shs	3.65 million shs
PTCT PTC Therapeutics	$48.92 +0.1%	$48.87	$30.41 ▼ $58.38	$3.88B	0.54	1.54 million shs	681,391 shs
TLX Telix Pharmaceuticals	$12.09 +10.2%	$14.55	$10.50 ▼ $30.36	$3.71B	N/A	97,845 shs	309,378 shs
VALN Valneva	$11.19 -2.7%	$7.30	$3.62 ▼ $12.25	$978.58M	1.77	104,869 shs	67,998 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LNTH Lantheus	+1.80%	+4.37%	-21.55%	-24.90%	-42.97%
PTCT PTC Therapeutics	-1.49%	+1.41%	+2.07%	+7.32%	+42.05%
TLX Telix Pharmaceuticals	-2.92%	-1.88%	-33.52%	-32.28%	+1,096,999,900.00%
VALN Valneva	+0.35%	+3.05%	+81.10%	+81.67%	+40.07%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
LNTH Lantheus	4.7499 of 5 stars	4.4	1.0	0.0	4.2	3.3	2.5	1.9
PTCT PTC Therapeutics	4.4267 of 5 stars	4.3	1.0	0.0	4.4	3.0	0.8	1.3
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VALN Valneva	2.3047 of 5 stars	3.5	3.0	0.0	0.0	2.9	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LNTH Lantheus	2.71	Moderate Buy	$105.50	78.33% Upside
PTCT PTC Therapeutics	2.63	Moderate Buy	$69.15	41.36% Upside
TLX Telix Pharmaceuticals	3.00	Buy	$22.33	84.73% Upside
VALN Valneva	3.00	Buy	$16.00	42.98% Upside

Current Analyst Ratings Breakdown

Latest VALN, TLX, PTCT, and LNTH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2025	PTCT PTC Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$79.00 ➝ $73.00
8/20/2025	PTCT PTC Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$76.00 ➝ $71.00
8/20/2025	PTCT PTC Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$82.00 ➝ $76.00
8/19/2025	VALN Valneva	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$18.00
8/11/2025	LNTH Lantheus	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Hold	$111.00 ➝ $63.00
8/8/2025	PTCT PTC Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$70.00
8/8/2025	PTCT PTC Therapeutics	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
8/8/2025	PTCT PTC Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$60.00 ➝ $63.00
8/8/2025	PTCT PTC Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$78.00 ➝ $79.00
8/7/2025	LNTH Lantheus	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$112.00 ➝ $73.00
8/7/2025	LNTH Lantheus	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$120.00 ➝ $70.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LNTH Lantheus	$1.53B	2.62	$7.61 per share	7.77	$17.16 per share	3.45
PTCT PTC Therapeutics	$806.78M	4.82	N/A	N/A	($2.60) per share	-18.82
TLX Telix Pharmaceuticals	$516.72M	7.92	$0.12 per share	98.96	$1.12 per share	10.79
VALN Valneva	$183.52M	5.19	$0.10 per share	117.29	$2.49 per share	4.49

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LNTH Lantheus	$312.44M	$3.76	15.73	9.38	N/A	17.82%	34.06%	19.10%	11/5/2025 (Estimated)
PTCT PTC Therapeutics	-$363.30M	$6.97	7.02	N/A	N/A	35.65%	-106.31%	30.61%	11/6/2025 (Estimated)
TLX Telix Pharmaceuticals	$32.93M	N/A	0.00	25.19	N/A	N/A	N/A	N/A	8/21/2025 (Estimated)
VALN Valneva	-$13.25M	-$0.98	N/A	N/A	N/A	-33.87%	-34.78%	-13.43%	11/6/2025 (Estimated)

Latest VALN, TLX, PTCT, and LNTH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/21/2025	H1 2025	TLX Telix Pharmaceuticals	$0.2160	-$0.0068	-$0.2228	N/A	$316.69 million	$390.36 million
8/12/2025	Q2 2025	VALN Valneva	-$0.27	-$0.16	+$0.11	-$0.16	$46.28 million	$54.84 million
8/7/2025	Q2 2025	PTCT PTC Therapeutics	-$1.07	-$0.83	+$0.24	-$0.83	$173.01 million	$178.88 million
8/6/2025	Q2 2025	LNTH Lantheus	$1.65	$1.57	-$0.08	$1.12	$389.69 million	$378.05 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VALN Valneva	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LNTH Lantheus	0.49	4.29	4.07
PTCT PTC Therapeutics	N/A	3.62	3.57
TLX Telix Pharmaceuticals	0.99	2.78	2.66
VALN Valneva	0.66	2.27	1.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LNTH Lantheus	99.06%
PTCT PTC Therapeutics	N/A
TLX Telix Pharmaceuticals	N/A
VALN Valneva	11.39%

Insider Ownership

Company	Insider Ownership
LNTH Lantheus	1.50%
PTCT PTC Therapeutics	5.50%
TLX Telix Pharmaceuticals	N/A
VALN Valneva	14.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LNTH Lantheus	700	67.99 million	66.97 million	Optionable
PTCT PTC Therapeutics	1,410	79.44 million	75.07 million	Optionable
TLX Telix Pharmaceuticals	N/A	338.40 million	N/A	N/A
VALN Valneva	700	85.09 million	72.41 million	Not Optionable

VALN, TLX, PTCT, and LNTH Headlines

Recent News About These Companies

Valneva (NASDAQ:VALN) Given Buy Rating at HC Wainwright

August 21 at 8:10 AM | marketbeat.com

HC Wainwright Begins Coverage on Valneva (NASDAQ:VALN)

August 21 at 2:37 AM | americanbankingnews.com

Valneva (NASDAQ:VALN) Sees Unusually-High Trading Volume - What's Next?

August 20 at 2:39 PM | marketbeat.com

Valneva’s chikungunya vaccine, Ixchiq receives Health Canada marketing authorization

August 19 at 8:01 PM | pharmabiz.comP

Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older

August 19 at 2:59 PM | finance.yahoo.com

Valneva’s Chikungunya Vaccine IXCHIQ® Gains Health Canada Approval

August 19 at 2:59 PM | msn.com

Valneva assumed with a Buy at H.C. Wainwright

August 19 at 2:59 PM | msn.com

Valneva SE Sponsored ADR (NASDAQ:VALN) Short Interest Update

August 19 at 4:27 AM | marketbeat.com

Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older

August 18 at 2:00 AM | globenewswire.com

Valneva (NASDAQ:VALN) Trading 14.3% Higher Following Strong Earnings

August 15, 2025 | marketbeat.com

Valneva (NASDAQ:VALN) Sets New 1-Year High - Time to Buy?

August 15, 2025 | marketbeat.com

A Vaccine for a Mosquito-Borne Disease Fuels Valneva Stock Rally

August 15, 2025 | bloomberg.com

Valneva (NASDAQ:VALN) Shares Gap Up Following Better-Than-Expected Earnings

August 13, 2025 | marketbeat.com

Valneva (NASDAQ:VALN) Announces Quarterly Earnings Results, Beats Estimates By $0.11 EPS

August 13, 2025 | marketbeat.com

Valneva (NASDAQ:VALN) Sees Strong Trading Volume - Time to Buy?

August 12, 2025 | marketbeat.com

Valneva SE 2025 Q2 - Results - Earnings Call Presentation

August 12, 2025 | seekingalpha.com

Valneva Shares Gain After Results, Outlook

August 12, 2025 | marketwatch.com

Valneva (NASDAQ:VALN) Trading Down 6.7% - Here's What Happened

August 12, 2025 | marketbeat.com

Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates

August 12, 2025 | globenewswire.com

Valneva SE (VALN) Q2 2025: Everything You Need To Know Ahead Of Earnings

August 11, 2025 | finance.yahoo.com

Valneva (VALN) Expected to Announce Quarterly Earnings on Tuesday

August 11, 2025 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VALN, TLX, PTCT, and LNTH Company Descriptions

Lantheus NASDAQ:LNTH

$59.16 +3.02 (+5.38%)

Closing price 04:00 PM Eastern

Extended Trading

$59.08 -0.08 (-0.14%)

As of 07:52 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

PTC Therapeutics NASDAQ:PTCT

$48.92 +0.07 (+0.14%)

Closing price 04:00 PM Eastern

Extended Trading

$48.92 +0.00 (+0.00%)

As of 05:14 PM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Telix Pharmaceuticals NASDAQ:TLX

$12.09 +1.12 (+10.21%)

Closing price 04:00 PM Eastern

Extended Trading

$12.08 -0.02 (-0.12%)

As of 07:55 PM Eastern

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

Valneva NASDAQ:VALN

$11.19 -0.31 (-2.70%)

Closing price 04:00 PM Eastern

Extended Trading

$11.33 +0.14 (+1.25%)

As of 06:59 PM Eastern

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time